It also affects your brain and central nervous system pathways that regulate digestion, potentially contributing to altered bowel function beyond the direct GI tract effects
In a Phase I single-blind, placebo-controlled trial, 3 male volunteers received subcutaneous MT-2 injections (0.01-0.03 mg/kg) on alternating days for 2 weeks
The headline number depends entirely on which estimand you quote, and the two figures are not interchangeable: 20.4% mean body-weight change at week 68 with CagriSema vs 3.0% with placebo (estimated difference 17.3 percentage points
This will help them adjust the medication dosage to fit the patient's needs better
Gastrointestinal side effects are dose-dependent and most common when starting treatment, typically improving after 48 weeks as the body adapts
Difficulty Achieving Long-Term Weight Loss Individuals who have made consistent efforts with diet and physical activity but continue to struggle with sustained weight management may benefit from medications that target appetite regulation